Continuous, high-dose progestogen treatment of endometrial cancer.

Gynecol Obstet Invest

Department of Obstetrics and Gynecology, Semmelweis University Medical School, Budapest, Hungary.

Published: February 1988

The morphological effect of a high-dose progestogen (Depo-Provera) on highly differentiated endometrial carcinoma was studied. Thirteen patients were treated by progestogen only, given at the beginning of the treatment in a weekly dose of 1,000 mg for 3 month. Then, progestogen 500 mg was administered for 12 months. Nine patients were operated after the treatment; in 7 of them, a total histological regression was observed. Histological tests of the intraoperatively gained preparations showed 'disappearance' of the original carcinomatous process; only a serious atrophy of the endometrium could be detected.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000298812DOI Listing

Publication Analysis

Top Keywords

high-dose progestogen
8
progestogen treatment
8
continuous high-dose
4
progestogen
4
treatment endometrial
4
endometrial cancer
4
cancer morphological
4
morphological high-dose
4
progestogen depo-provera
4
depo-provera highly
4

Similar Publications

High-Dose Cyproterone Acetate and Intracranial Meningioma: Impact of the Risk Minimisation Measures Implemented in France in 2018-2019.

Pharmacoepidemiol Drug Saf

January 2025

EPI-PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products-ANSM, French National Health Insurance-CNAM), Saint-Denis, France.

Purpose: To measure the impact of national regulatory actions implemented in France in August 2018 and June 2019 to reduce the risk of meningioma associated with the use of cyproterone acetate (CPA).

Methods: Using the French National Healthcare database, we calculated the monthly number of CPA users among cisgender women, men and transgender women in 2010-2021, the monthly proportion of users with cerebral imaging screening, and the annual rate of meningioma surgery associated with CPA use. CPA discontinuations and switches were analysed.

View Article and Find Full Text PDF

Prolactin Response to a Submaximal Dose of Ghrelin in Different Phases of the Normal Menstrual Cycle.

Medicina (Kaunas)

December 2024

Department of Obstetrics and Gynaecology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece.

A similar secretory pattern of prolactin (PRL) and growth hormone (GH) during the menstrual cycle has been reported in response to a high dose of ghrelin in adult healthy women. The present study aimed to assess the pattern of PRL and GH secretions in response to a submaximal dose of ghrelin during different menstrual phases in adult healthy women. Eight female subjects with normal cyclicity were enrolled.

View Article and Find Full Text PDF

Introduction: Current trends of delaying childbearing and the increasing incidence of endometrial cancer in nulliparous woman necessitate research and development of fertility sparing treatments. Hormonal therapy with progestins offers an alternative to surgical treatment for a select group of patients of reproductive-age, who wish to preserve their reproductive potential.

Materials And Methods: The study evaluates the effectiveness of medroxyprogesterone acetate therapy in patients with early-stage endometrial cancer, atypical endometrial hyperplasia or atypical polypoid adenomyoma, seeking to preserve fertility.

View Article and Find Full Text PDF

The aim of the present study was to investigate the role of ovarian hormones on dopaminergic regulation of prepulse inhibition (PPI), a measure of sensorimotor gating deficient in schizophrenia and other psychiatric illnesses. Either in adulthood (11 weeks of age) or adolescence (5 weeks of age), female mice underwent ovariectomy (OVX) and were implanted with 17β-estradiol, progesterone, or a combination of these hormones. All mice were tested in adulthood for the acute effect of the dopamine receptor agonist, apomorphine, on PPI.

View Article and Find Full Text PDF

GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol.

Trials

September 2024

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Obstetric and Gynecologic Diseases, No. 1 ShuaiFuYuan, Dongcheng District, Beijing, 100730, China.

Background: Around 4% of women receive an endometrial cancer diagnosis before turning 40, mainly those without prior childbirth experience and a strong desire to preserve their ability to conceive. Consequently, for young patients diagnosed with atypical endometrial hyperplasia (AEH) or early endometrial carcinoma (EC), a fertility-preserving approach employing high-dose oral progesterone has been adopted. However, previous research has shown a notable relapse rate.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!